Brokerages Set Becton Dickinson (BDX) Price Target at $240.00

Shares of Becton Dickinson (NYSE:BDX) have earned an average rating of “Buy” from the eighteen analysts that are presently covering the firm, Marketbeat reports. Five research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $240.00.

Several brokerages have commented on BDX. BMO Capital Markets began coverage on Becton Dickinson in a research report on Monday, March 5th. They issued a “market perform” rating and a $249.00 price objective on the stock. Citigroup raised Becton Dickinson from a “neutral” rating to a “buy” rating and upped their price objective for the company from $237.00 to $251.00 in a research report on Tuesday, April 10th. Morgan Stanley upped their price objective on Becton Dickinson from $245.00 to $250.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 7th. Zacks Investment Research downgraded Becton Dickinson from a “buy” rating to a “hold” rating in a research report on Tuesday, March 6th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $260.00 price objective (up previously from $223.00) on shares of Becton Dickinson in a research report on Tuesday, February 6th.

Becton Dickinson stock traded down $1.87 during mid-day trading on Friday, hitting $223.73. The company’s stock had a trading volume of 1,027,711 shares, compared to its average volume of 1,321,785. The company has a market capitalization of $60.45 billion, a PE ratio of 23.60, a price-to-earnings-growth ratio of 1.57 and a beta of 1.15. The company has a quick ratio of 1.12, a current ratio of 1.70 and a debt-to-equity ratio of 1.07. Becton Dickinson has a one year low of $185.33 and a one year high of $248.39.

Becton Dickinson (NYSE:BDX) last announced its quarterly earnings data on Thursday, May 3rd. The medical instruments supplier reported $2.65 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.63 by $0.02. The company had revenue of $4.22 billion for the quarter, compared to the consensus estimate of $4.12 billion. Becton Dickinson had a positive return on equity of 14.27% and a negative net margin of 0.46%. Becton Dickinson’s quarterly revenue was up 42.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.30 EPS. research analysts anticipate that Becton Dickinson will post 10.99 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, June 29th. Stockholders of record on Friday, June 8th will be given a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.34%. The ex-dividend date of this dividend is Thursday, June 7th. Becton Dickinson’s payout ratio is 31.65%.

In related news, EVP Thomas E. Polen, Jr. sold 1,877 shares of the company’s stock in a transaction on Tuesday, March 13th. The stock was sold at an average price of $227.00, for a total transaction of $426,079.00. Following the completion of the sale, the executive vice president now directly owns 15,387 shares in the company, valued at approximately $3,492,849. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Alexandre Conroy sold 20,128 shares of the company’s stock in a transaction on Monday, May 21st. The stock was sold at an average price of $228.74, for a total value of $4,604,078.72. Following the sale, the insider now owns 35,583 shares of the company’s stock, valued at $8,139,255.42. The disclosure for this sale can be found here. Insiders have sold a total of 41,608 shares of company stock worth $9,457,755 in the last three months. Corporate insiders own 1.00% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. BlackRock Inc. lifted its stake in shares of Becton Dickinson by 0.7% during the 1st quarter. BlackRock Inc. now owns 18,936,564 shares of the medical instruments supplier’s stock worth $4,103,552,000 after purchasing an additional 125,262 shares during the last quarter. Franklin Resources Inc. lifted its stake in shares of Becton Dickinson by 1.5% during the 1st quarter. Franklin Resources Inc. now owns 3,744,936 shares of the medical instruments supplier’s stock worth $811,527,000 after purchasing an additional 55,004 shares during the last quarter. Northern Trust Corp lifted its stake in shares of Becton Dickinson by 8.1% during the 1st quarter. Northern Trust Corp now owns 3,319,529 shares of the medical instruments supplier’s stock worth $719,341,000 after purchasing an additional 247,339 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Becton Dickinson by 3.4% during the 4th quarter. Geode Capital Management LLC now owns 2,216,435 shares of the medical instruments supplier’s stock worth $473,373,000 after purchasing an additional 72,358 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its stake in shares of Becton Dickinson by 1,192.1% during the 4th quarter. Renaissance Technologies LLC now owns 2,074,503 shares of the medical instruments supplier’s stock worth $444,068,000 after purchasing an additional 1,913,952 shares during the last quarter. Hedge funds and other institutional investors own 84.45% of the company’s stock.

Becton Dickinson Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Analyst Recommendations for Becton Dickinson (NYSE:BDX)

Receive News & Ratings for Becton Dickinson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply